ERBB2 and adenocarcinoma: The ToGA-trial showed a HER-2 positivity of 22.1% [20][24] in gastric cancer and adenocarcinoma of the gastro-esophageal junction (overall n = 584 HER-2 positive) using a specific modified immunohistochemistry (IHC) scoring algorithm in comparison to breast cancer [20][25].